ArticleArtificial organs2025
In Vitro Evaluation of Liposomal Amphotericin B Adsorption With Different Hemofilters for Continuous Hemofiltration.
Article in Artificial organs, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Technicalities, current evidence, and clinical indications of hemoadsorption in critically ill children.Pediatric nephrology (Berlin, Germany) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundFungemia is an infectious disease with a poor prognosis. Continuous hemofiltration (CHF) is widely used for the treatment of acute kidney injury associated with fungemia. However, the effect of hemofiltration membranes for CHF on antifungal drug concentrations remains poorly understood. Therefore, clarifying the adsorption of antifungal drugs onto these membranes is important. We investigated the adsorption properties of liposomal amphotericin B on different hemofiltration membranes using closed-circulation hemofiltration.
methodsWe performed hemofiltration with each solution adjusted to liposomal amphotericin B as a closed circulatory circuit using polyacrylonitrile (AN69ST), polymethyl methacrylate (PMMA), and polysulfone (PS) membranes. Only this circuit was used as a control. Amphotericin B concentration at the inlet and in the effluent of the hemofiltration membrane was measured. The adsorption rate (Ra) of amphotericin B was then calculated.
resultsThe concentration of amphotericin B decreased in the PS membranes compared to that in the controls after 15 min (p = 0.03). The Ra of amphotericin B was higher in PS membranes than in the controls (p = 0.02). Amphotericin B was not adsorbed onto the PMMA or AN69ST membranes. The concentration of amphotericin B in these membranes showed no change compared with that in the control after 1440 min. Liposomal amphotericin B was temporarily absorbed on PS membranes, but at clinical doses, it did not appear to affect the antifungal doses.
conclusionsDifferent blood purification membranes can be used to treat CHF without affecting the administration of antifungal drugs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.